XENE Xenon Pharmaceuticals Inc.

3.95
+0.00  (0%)
Previous Close 3.95
Open 3.95
Price To book 1.24
Market Cap 71.08M
Shares 17,996,000
Volume 9,752
Short Ratio 1.75
Av. Daily Volume 158,394

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827217
  2. 8-K - Current report 17826812
  3. DEF 14A - Other definitive proxy statements 17789009
  4. 8-K - Current report 17784947
  5. 8-K - Current report 17713256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released March 24, 2017 - endpoints not met.
XEN801
Acne
Phase 2b initiated late March 2015. Data due mid-2017.
TV-45070
Postherpetic neuralgia
Phase 2b trial did not meet endpoints - July 2015
TV-45070
Osteoarthritis

Latest News

  1. Edited Transcript of XENE earnings conference call or presentation 9-May-17 8:30pm GMT
  2. Xenon Pharmaceuticals reports 1Q loss
  3. Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
  4. Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call
  5. Xenon Pharmaceuticals to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference
  6. Nuventra founder inks deal for new venture that could be worth as much as $49 million
  7. Xenon Expands Ion Channel Neurology Pipeline with Acquisition of New Potassium Channel Modulator for the Treatment of Epilepsy
  8. 3 of the Best & Worst Performing Drug Stocks of Q1
  9. Xenon Pharmaceuticals Falls as Acne Drug Fails Study, Pulse Biosciences Submits 510(k) to FDA
  10. Xenon Pharma Dumps Acne Drug After Study Failure
  11. Xenon Pharmaceuticals' acne drug fails mid-stage study
  12. Xenon Pharmaceuticals Announces XEN801 Did Not Meet Efficacy Endpoints in Phase 2 Clinical Trial in Patients with Moderate to Severe Acne
  13. Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  14. Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  15. Edited Transcript of XENE earnings conference call or presentation 8-Mar-17 9:30pm GMT
  16. Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update
  17. Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2016 Financial Results and Provide Corporate Update
  18. How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers
  19. Edited Transcript of XENE earnings conference call or presentation 3-Nov-16 8:30pm GMT

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827217
  2. 8-K - Current report 17826812
  3. DEF 14A - Other definitive proxy statements 17789009
  4. 8-K - Current report 17784947
  5. 8-K - Current report 17713256
  6. 8-K - Current report 17688137
  7. 8-K - Current report 17679035
  8. S-8 - Securities to be offered to employees in employee benefit plans 17675878
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17675675
  10. 8-K - Current report 17675248